Literature DB >> 7899238

Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (Sandostatin) in the rabbit.

D T Lau1, J W Sharkey, L Petryk, F A Mancuso, Z Yu, F L Tse.   

Abstract

The effect of current magnitude and drug concentration on transdermal iontophoretic delivery of octreotide acetate (Sandostatin) was examined in the rabbit. Plasma samples were collected over 24 hours and octreotide concentrations were determined by a radioimmunoassay. Without an electrical current, negligible plasma concentrations of octreotide were obtained. Following initiation of iontophoresis, plasma concentrations of octreotide increased rapidly, although did not sustain at a plateau level during the dosing period. Octreotide concentrations declined rapidly after removal of the device. Increasing the electrical current from 50 microA/cm2 to 150 microA/cm2 yielded a proportional increase in the delivery. Increasing the drug concentration in the device from 2.5 mg/mL to 5 mg/mL resulted in approximately proportional increase in plasma octreotide concentrations; however, further increase in plasma concentrations was not observed for drug concentrations beyond 5 mg/mL. Iontophoretic delivery at the conditions which yielded the highest octreotide concentrations in this study (5 mg/mL solution at 150 microA/cm2 for 8 hours) yielded an apparent bioavailability (which represents an underestimate of the absolute bioavailability determined when the patches are run to exhaustion) of approximately 8%.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7899238     DOI: 10.1023/a:1018963300092

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Comparison between the iontophoretic and passive transport of thyrotropin releasing hormone across excised nude mouse skin.

Authors:  R R Burnette; D Marrero
Journal:  J Pharm Sci       Date:  1986-08       Impact factor: 3.534

Review 2.  Iontophoresis--is there a future for clinical application?

Authors:  U Theiss; I Kuhn; P W Lücker
Journal:  Methods Find Exp Clin Pharmacol       Date:  1991-06

3.  Five modified numerical deconvolution methods for biopharmaceutics and pharmacokinetics studies.

Authors:  Z Yu; J B Schwartz; E T Sugita; H C Foehl
Journal:  Biopharm Drug Dispos       Date:  1996-08       Impact factor: 1.627

4.  Disposition of sandostatin, a new synthetic somatostatin analogue, in rats.

Authors:  M Lemaire; M Azria; R Dannecker; P Marbach; A Schweitzer; G Maurer
Journal:  Drug Metab Dispos       Date:  1989 Nov-Dec       Impact factor: 3.922

5.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

6.  Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

Authors:  S W Lamberts; P Uitterlinden; L Verschoor; K J van Dongen; E del Pozo
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

7.  Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

Authors:  S M Wood; M E Kraenzlin; T E Adrian; S R Bloom
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

8.  Mathematical basis of point-area deconvolution method for determining in vivo input functions.

Authors:  D P Vaughan; M Dennis
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

9.  Enteral absorption of octreotide.

Authors:  G Fricker; J Drewe; J Vonderscher; T Kissel; C Beglinger
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

10.  Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration.

Authors:  E del Pozo; M Neufeld; K Schlüter; F Tortosa; P Clarenbach; E Bieder; L Wendel; E Nüesch; P Marbach; H Cramer
Journal:  Acta Endocrinol (Copenh)       Date:  1986-04
View more
  6 in total

1.  Transdermal iontophoretic delivery of vapreotide acetate across porcine skin in vitro.

Authors:  Yannic B Schuetz; Aarti Naik; Richard H Guy; Evelyne Vuaridel; Yogeshvar N Kalia
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

Review 2.  Transdermal delivery of proteins.

Authors:  Haripriya Kalluri; Ajay K Banga
Journal:  AAPS PharmSciTech       Date:  2011-03-03       Impact factor: 3.246

3.  Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances.

Authors:  J Hirvonen; R H Guy
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

Review 4.  Advances in transdermal insulin delivery.

Authors:  Yuqi Zhang; Jicheng Yu; Anna R Kahkoska; Jinqiang Wang; John B Buse; Zhen Gu
Journal:  Adv Drug Deliv Rev       Date:  2018-12-08       Impact factor: 15.470

5.  Transdermal delivery of cytochrome C--A 12.4 kDa protein--across intact skin by constant-current iontophoresis.

Authors:  J Cázares-Delgadillo; A Naik; A Ganem-Rondero; D Quintanar-Guerrero; Y N Kalia
Journal:  Pharm Res       Date:  2007-04-25       Impact factor: 4.200

6.  Enhanced Skin Delivery of Therapeutic Peptides Using Spicule-Based Topical Delivery Systems.

Authors:  Chi Zhang; Jiwen Duan; Yongxiang Huang; Ming Chen
Journal:  Pharmaceutics       Date:  2021-12-08       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.